[시장보고서]두개내 치료 전달 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

두개내 치료 전달 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Intracranial Therapeutic Delivery Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

상품코드 : 1495354

리서치사 : Persistence Market Research

발행일 : 2024년 06월

페이지 정보 : 영문 168 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,421,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,838,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,621,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 세계의 두개내 치료 전달 시장의 종합적 분석을 발표하고, 시장 역학, 성장 전망, 과제, 신규 동향에 관한 인사이트를 제공하고 있습니다. 2024-2032년의 시장의 궤적을 예측한 독점 데이터와 통계를 제공하고 있습니다.

시장 개요 :

2024년 시장 규모는 22억 달러에 달하며, 2032년의 예측 시장 규모는 42억 달러에 달하며, 2024-2032년의 CAGR은 7.9%에 달할 전망입니다.

주요 인사이트

시장 규모(2024년) : 22억 달러
시장 예측치(2032년) : 42억 달러
성장률(2024-2032년) : 7.9%의 CAGR

두개내 치료 전달 시장 보고서

두개내 치료 전달 시장 구도를 조사했으며, 시장 도입 촉진요인, 규제 상황, 시장 역학을 형성하는 기술 발전에 초점을 맞추었습니다.

시장 성장 촉진요인 :

신경질환의 유병률 증가, 약물전달 기술의 발전, 의료 인프라에 대한 투자 증가 등의 요인으로 인해 시장이 성장하고 있습니다. 또한 정부 지원책과 환자 중심의 치료 접근법에 대한 관심 증가도 시장 확대에 기여하고 있습니다.

시장 성장 억제요인 :

시장이 직면한 과제에는 규제 장벽, 안전성 및 유효성에 대한 우려, 두개내 치료 전달 시스템과 관련된 높은 개발 비용 등이 있습니다. 또한 신경질환의 복잡성과 환자 반응의 다양성이 시장 침투에 걸림돌로 작용하고 있습니다.

시장 기회 :

"도전과제도 있지만, 시장에는 혁신과 성장의 큰 기회가 있습니다. 약물전달의 효율성을 높이고 부작용을 최소화하기 위한 지속적인 연구개발이 필수적입니다. 또한 제약사, 연구기관, 규제당국의 전략적 제휴를 통해 새로운 전달 시스템 개발을 촉진하고, 미충족 의료 수요를 충족시키고 시장을 확대할 수 있습니다.

이 보고서에서 다룬 주요 질문

두개내 치료 전달 시장의 성장을 가속하는 요인은 무엇인가?
두개내 치료 전달 시스템을 관리하는 현재의 규제 프레임워크는?
시장 상황을 지배하는 주요 기업은?
어떤 신흥 트렌드와 미래 전망이 예측되는가?

경쟁사 분석 :

매우 역동적인 두개내 치료 전달의 전망에서 Novartis AG, BioMarin, Bayer AG와 같은 주요 기업이 탄탄한 R&D 노력으로 선두를 달리고 있습니다. CORESTEM Inc., Alaunos Therapeutics, Inc. 및 Apic Bio는 틈새 치료 분야에 집중하고 최첨단 기술을 활용하여 시장 주도권을 확보하기 위해 노력하고 있습니다. Stemedica Cell Technologies, Inc.와 Voyager Therapeutics는 세포 기반 치료에 중점을 두고 신경퇴행성 질환에 대한 유망한 솔루션을 제공함으로써 주목받고 있습니다. 유망한 솔루션을 제공하고 있으며, 주목받고 있습니다. 또한 아베오나 테라퓨틱스(Aveona Therapeutics)와 스파크 테라퓨틱스(Spark Therapeutics)와 같은 기업은 유전자 치료 접근법을 통해 혁신을 가져와 치료의 전망을 재구성하고 있습니다. 경쟁이 심화되는 가운데, 전략적 제휴와 연구개발에 대한 투자는 시장 경쟁력을 유지하고 미래 성장을 가속하는 데 있으며, 계속 중요할 것으로 보입니다.

서론
과거 시장 규모(금액) 동향 분석 : 시장 분류별, 2019-2023년
현재 및 향후 시장 규모(금액) 분석과 예측 : 시장 분류별, 2024-2032년
- 요법별
- 적응증별
시장의 매력 분석
주요 시장 참여 기업-강도 매핑
촉진요인과 억제요인 - 영향 분석

제12장 유럽의 두개내 치료 전달 시장 분석

제13장 세계의 기타 지역(ROW) 두개내 치료 전달 시장 분석

제14장 시장 구조 분석

기업 계층별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석

제15장 경쟁 분석

경쟁 대시보드
경쟁 벤치마킹
경쟁의 상세[잠정 리스트]
- Novartis AG
- BioMarin
- CORESTEM Inc.
- Alaunos Therapeutics, Inc.
- Apic Bio
- Stemedica Cell Technologies, Inc.
- Voyager Therapeutics
- Bayer AG
- Abeona Therapeutics
- Spark Therapeutics

제16장 사용되는 전제 조건과 두자어

제17장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research has released a comprehensive analysis of the global Intracranial Therapeutic Delivery Market, providing insights into market dynamics, growth prospects, challenges, and emerging trends. This report offers exclusive data and statistics projecting the market's trajectory from 2024 to 2032.

Market Overview:

The market size in 2024 is US$ 2.2 billion. The projected market value for 2032 is US$ 4.2 billion, with a CAGR of 7.9% from 2024 to 2032.

Key Insights:

Market Size (2024): US$ 2.2 Bn
Projected Market Value (2032): US$ 4.2 Bn
Growth Rate (2024-2032): 7.9% CAGR

Intracranial Therapeutic Delivery Market Report:

This report delves into the landscape of intracranial therapeutic delivery, focusing on factors driving market adoption, regulatory considerations, and technological advancements shaping market dynamics.

Market Growth Drivers:

The market is propelled by factors such as the increasing prevalence of neurological disorders, advancements in drug delivery technologies, and rising investments in healthcare infrastructure. Additionally, supportive government initiatives and a growing focus on patient-centric treatment approaches contribute to market expansion.

Market Restraints:

Challenges facing the market include regulatory hurdles, concerns regarding safety and efficacy, and high development costs associated with intracranial therapeutic delivery systems. Moreover, the complexity of neurological conditions and variability in patient responses present hurdles for market penetration.

Market Opportunities:

Despite challenges, the market presents significant opportunities for innovation and growth. Continued research and development efforts aimed at enhancing drug delivery efficiency and minimizing side effects are essential. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and regulatory bodies can foster the development of novel delivery systems, addressing unmet medical needs and expanding market reach.

Key Questions Answered in the Report:

What factors are driving the growth of the Intracranial Therapeutic Delivery Market?
What are the current regulatory frameworks governing intracranial therapeutic delivery systems?
Which key players dominate the market landscape?
What emerging trends and future prospects are anticipated?

Competitive Analysis:

In the highly dynamic landscape of intracranial therapeutic delivery, key players such as Novartis AG, BioMarin, and Bayer AG are leading the charge with their robust research and development efforts. These companies leverage their extensive expertise and resources to innovate novel delivery systems and advance treatment options for neurological disorders. CORESTEM Inc., Alaunos Therapeutics, Inc., and Apic Bio are emerging as formidable contenders, focusing on niche therapeutic areas and leveraging cutting-edge technologies to gain market traction. Stemedica Cell Technologies, Inc. and Voyager Therapeutics are notable for their emphasis on cell-based therapies, offering promising solutions for neurodegenerative diseases. Furthermore, companies like Abeona Therapeutics and Spark Therapeutics bring innovation through gene therapy approaches, reshaping the treatment landscape. Amidst intensifying competition, strategic collaborations and investments in research and development remain critical for maintaining market competitiveness and driving future growth.

Key Companies Profiled:

Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics

Market Segmentation:

Intracranial Therapeutic Delivery Market by Therapy:

Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy

Intracranial Therapeutic Delivery Market by Indication:

Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis

Intracranial Therapeutic Delivery Market by Region:

U.S. Intracranial Therapeutic Delivery Market
Europe Intracranial Therapeutic Delivery Market
Rest of the World (ROW) Intracranial Therapeutic Delivery Market

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions / Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Disease Epidemiology
4.2. Key Promotional Strategies, By Manufacturers
4.3. Porter's Analysis
4.4. PESTLE Analysis
4.5. Value Chain

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Top Companies Historical Growth
- 5.2.2. GDP Growth forecast
- 5.2.3. Strategic Collaborations among Players
- 5.2.4. Rising Number of Pipeline Products for Gene-Based Therapies
- 5.2.5. Growing prevalence of Neurologic Diseases
- 5.2.6. Entries of new start-up companies in the market
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. 2024 Market Scenario
6.2. COVID-19 and Impact Analysis
- 6.2.1. Revenue by Therapy
- 6.2.2. Revenue by Indication
- 6.2.3. Revenue by Country

7. Global Intracranial Therapeutic Delivery Market Demand (in Value or Size (US$ Bn) Analysis 2019-2023 and Forecast, 2024-2032

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032, By Therapy

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Trend Analysis By Therapy, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy, 2024-2032
- 8.3.1. Cell-Based Therapy
- 8.3.2. Gene Therapy
- 8.3.3. Enzyme Replacement Therapy
8.4. Market Attractiveness Analysis By Therapy

9. Global Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032, by Indication

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Trend Analysis By Indication, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2032
- 9.3.1. Spinal Muscular Atrophy (SMA)
- 9.3.2. Multiple Sclerosis
- 9.3.3. Batten Disease
- 9.3.4. Amyotrophic lateral sclerosis
9.4. Market Attractiveness Analysis By Indication

10. Global Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032, by Region

10.1. Introduction
10.2. Historical Market Size (US$ Bn) Trend Analysis, By Region, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2032
- 10.3.1. U.S.
- 10.3.2. Europe
- 10.3.3. Rest of the World (ROW)
10.4. Market Attractiveness Analysis By Region

11. U.S Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 11.3.1. By Therapy
- 11.3.2. By Indication
11.4. Market Attractiveness Analysis
- 11.4.1. By Therapy
- 11.4.2. By Indication
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis

12. Europe Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 12.3.1. By Country
  - 12.3.1.1. Germany
  - 12.3.1.2. Italy
  - 12.3.1.3. France
  - 12.3.1.4. U.K.
  - 12.3.1.5. Spain
  - 12.3.1.6. BENELUX
  - 12.3.1.7. Nordic Countries
  - 12.3.1.8. Russia
  - 12.3.1.9. Rest of Europe
- 12.3.2. By Therapy
- 12.3.3. By Indication
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Therapy
- 12.4.3. By Indication
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
- 12.7.1. Germany Intracranial Therapeutic Delivery Market
  - 12.7.1.1. Introduction
  - 12.7.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.1.2.1. By Therapy
    - 12.7.1.2.2. By Indication
- 12.7.2. France Intracranial Therapeutic Delivery Market
  - 12.7.2.1. Introduction
  - 12.7.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.2.2.1. By Therapy
    - 12.7.2.2.2. By Indication
- 12.7.3. Italy Intracranial Therapeutic Delivery Market
  - 12.7.3.1. Introduction
  - 12.7.3.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.3.2.1. By Therapy
    - 12.7.3.2.2. By Indication
- 12.7.4. Spain Intracranial Therapeutic Delivery Market
  - 12.7.4.1. Introduction
  - 12.7.4.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.4.2.1. By Therapy
    - 12.7.4.2.2. By Indication
- 12.7.5. U.K. Intracranial Therapeutic Delivery Market
  - 12.7.5.1. Introduction
  - 12.7.5.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.5.2.1. By Therapy
    - 12.7.5.2.2. By Indication
- 12.7.6. Benelux Union Intracranial Therapeutic Delivery Market
  - 12.7.6.1. Introduction
  - 12.7.6.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.6.2.1. By Therapy
    - 12.7.6.2.2. By Indication
- 12.7.7. Nordic Countries Intracranial Therapeutic Delivery Market
  - 12.7.7.1. Introduction
  - 12.7.7.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.7.2.1. By Therapy
    - 12.7.7.2.2. By Indication
- 12.7.8. Russia Intracranial Therapeutic Delivery Market
  - 12.7.8.1. Introduction
  - 12.7.8.2. Market Analysis and Forecast by Market Taxonomy
    - 12.7.8.2.1. By Therapy
    - 12.7.8.2.2. By Indication

13. Rest of the World (ROW) Intracranial Therapeutic Delivery Market Analysis 2019-2023 and Forecast 2024-2032

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 13.3.1. By Therapy
- 13.3.2. By Indication
13.4. Market Attractiveness Analysis
- 13.4.1. By Therapy
- 13.4.2. By Indication
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis

14. Market Structure Analysis

14.1. Market Analysis by Tier of Companies
14.2. Market Share Analysis of Top Players
14.3. Market Presence Analysis
- 14.3.1. By Regional footprint of Players
- 14.3.2. Product footprint by Players
- 14.3.3. Channel Foot Print by Players

15. Competition Analysis

15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Competition Deep Dive [Tentative list]
- 15.3.1. Novartis AG
  - 15.3.1.1. Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. Key Financials
  - 15.3.1.4. SWOT Analysis
  - 15.3.1.5. Sales Footprint
  - 15.3.1.6. Strategy Overview
  - 15.3.1.7. Key Developments
- 15.3.2. BioMarin
  - 15.3.2.1. Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. Key Financials
  - 15.3.2.4. SWOT Analysis
  - 15.3.2.5. Sales Footprint
  - 15.3.2.6. Strategy Overview
  - 15.3.2.7. Key Developments
- 15.3.3. CORESTEM Inc.
  - 15.3.3.1. Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. Key Financials
  - 15.3.3.4. SWOT Analysis
  - 15.3.3.5. Sales Footprint
  - 15.3.3.6. Strategy Overview
  - 15.3.3.7. Key Developments
- 15.3.4. Alaunos Therapeutics, Inc.
  - 15.3.4.1. Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. Key Financials
  - 15.3.4.4. SWOT Analysis
  - 15.3.4.5. Sales Footprint
  - 15.3.4.6. Strategy Overview
  - 15.3.4.7. Key Developments
- 15.3.5. Apic Bio
  - 15.3.5.1. Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. Key Financials
  - 15.3.5.4. SWOT Analysis
  - 15.3.5.5. Sales Footprint
  - 15.3.5.6. Strategy Overview
  - 15.3.5.7. Key Developments
- 15.3.6. Stemedica Cell Technologies, Inc.
  - 15.3.6.1. Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. Key Financials
  - 15.3.6.4. SWOT Analysis
  - 15.3.6.5. Sales Footprint
  - 15.3.6.6. Strategy Overview
  - 15.3.6.7. Key Developments
- 15.3.7. Voyager Therapeutics
  - 15.3.7.1. Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. Key Financials
  - 15.3.7.4. SWOT Analysis
  - 15.3.7.5. Sales Footprint
  - 15.3.7.6. Strategy Overview
  - 15.3.7.7. Key Developments
- 15.3.8. Bayer AG
  - 15.3.8.1. Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. Key Financials
  - 15.3.8.4. SWOT Analysis
  - 15.3.8.5. Sales Footprint
  - 15.3.8.6. Strategy Overview
  - 15.3.8.7. Key Developments
- 15.3.9. Abeona Therapeutics
  - 15.3.9.1. Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. Key Financials
  - 15.3.9.4. SWOT Analysis
  - 15.3.9.5. Sales Footprint
  - 15.3.9.6. Strategy Overview
  - 15.3.9.7. Key Developments
- 15.3.10. Spark Therapeutics
  - 15.3.10.1. Overview
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. Key Financials
  - 15.3.10.4. SWOT Analysis
  - 15.3.10.5. Sales Footprint
  - 15.3.10.6. Strategy Overview
  - 15.3.10.7. Key Developments

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 주요 시장 동향

제4장 주요 성공요인

제5장 시장 배경

제6장 COVID-19 위기 분석

제7장 세계의 두개내 치료 전달 시장의 수요(금액) 분석

제8장 세계의 두개내 치료 전달 시장 분석 : 요법별

제9장 세계의 두개내 치료 전달 시장 분석 : 적응증별

제10장 세계의 두개내 치료 전달 시장 분석 : 지역별

제11장 미국의 두개내 치료 전달 시장 분석